Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03126019 · ClinicalTrials.gov registry record · Phase 2
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT03126019 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 126 participants.
The verdict
NCT03126019, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.
Interventions
- DRUG Parsaclisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2018-03-14 |
| Est. Completion | 2024-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03126019
The ClinicalTrials.gov registry entry for NCT03126019 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Parsaclisib is the first listed.
NCT03126019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03126019 about?
NCT03126019 is a clinical study titled "A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma". The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.
What is the current status of trial NCT03126019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2018-03-14. Estimated completion is 2024-06-07.
What interventions are being tested in trial NCT03126019?
The interventions under investigation include: Parsaclisib (DRUG).
Who is sponsoring clinical trial NCT03126019?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.